Literature DB >> 21122634

When is equal not equal?

Allan D Sniderman1, Ken Williams, Matthew J McQueen, Curt D Furberg.   

Abstract

The meta-analysis of the Emerging Risk Factor Collaboration demonstrated that the hazard ratios (HR) of the major cholesterol markers and the major apolipoproteins for vascular disease did not differ significantly in the studies they examined. Their conclusion was that they were functionally interchangeable. We believe there are important limitations in the execution of this study. Nevertheless, even if their findings are correct for groups, their conclusions do not follow for individuals. Conventionally, the HR expresses the increase in risk per standard deviation change for that parameter in a group. However, the predicted risk of vascular disease from an atherogenic parameter depends on its concentration within the individual. Depending on the composition of the apoB lipoproteins, individuals may have either concordant or discordant levels of cholesterol and apoB. For those who are concordant, the two markers predict equal risk. For those who are discordant, the predicted risks for the individual are different. We demonstrate that substantial discordance in the individual HR of non-high-density lipoprotein cholesterol and apoB is common. The result is that even with identical overall HR, apoB points to higher risk in a substantial number of individuals whereas the converse is the case for non- high-density lipoprotein cholesterol. Because we are concerned with risks in individuals, not groups, this discordance is important to appreciate and analyze. Our objective should be to learn how to combine the information from parameters rather than eliminate them and we need to focus on evaluation of risk in individuals and not just groups.
Copyright © 2010 National Lipid Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21122634     DOI: 10.1016/j.jacl.2010.01.005

Source DB:  PubMed          Journal:  J Clin Lipidol        ISSN: 1876-4789            Impact factor:   4.766


  8 in total

Review 1.  Opening a new lipid "apo-thecary": incorporating apolipoproteins as potential risk factors and treatment targets to reduce cardiovascular risk.

Authors:  Terry A Jacobson
Journal:  Mayo Clin Proc       Date:  2011-08       Impact factor: 7.616

2.  Dose-response effects of marine omega-3 fatty acids on apolipoproteins, apolipoprotein-defined lipoprotein subclasses, and Lp-PLA2 in individuals with moderate hypertriglyceridemia.

Authors:  Ann C Skulas-Ray; Petar Alaupovic; Penny M Kris-Etherton; Sheila G West
Journal:  J Clin Lipidol       Date:  2014-12-11       Impact factor: 4.766

3.  Quantification of concordance and discordance between apolipoprotein-B and the currently recommended non-HDL-cholesterol goals for cardiovascular risk assessment in patients with diabetes and hypertriglyceridemia.

Authors:  O P Ganda; C G Jumes; M J Abrahamson; M Molla
Journal:  Diabetes Res Clin Pract       Date:  2012-03-28       Impact factor: 5.602

4.  Discordance between non-HDL-cholesterol and LDL-particle measurements: results from the Multi-Ethnic Study of Atherosclerosis.

Authors:  Emil M Degoma; Mat D Davis; Richard L Dunbar; Emile R Mohler; Philip Greenland; Benjamin French
Journal:  Atherosclerosis       Date:  2013-03-26       Impact factor: 5.162

Review 5.  Demystifying the management of hypertriglyceridaemia.

Authors:  Gerald F Watts; Esther M M Ooi; Dick C Chan
Journal:  Nat Rev Cardiol       Date:  2013-09-24       Impact factor: 32.419

6.  Comparison of various lipid variables as predictors of coronary heart disease in Japanese men and women with type 2 diabetes: subanalysis of the Japan Diabetes Complications Study.

Authors:  Hirohito Sone; Sachiko Tanaka; Shiro Tanaka; Satoshi Iimuro; Shun Ishibashi; Shinichi Oikawa; Hitoshi Shimano; Shigehiro Katayama; Yasuo Ohashi; Yasuo Akanuma; Nobuhiro Yamada
Journal:  Diabetes Care       Date:  2012-02-14       Impact factor: 19.112

Review 7.  Cholesteryl Ester Transfer Protein Inhibition Reduces Major Adverse Cardiovascular Events by Lowering Apolipoprotein B Levels.

Authors:  Adam J Nelson; Allan D Sniderman; Marc Ditmarsch; Mary R Dicklin; Stephen J Nicholls; Michael H Davidson; John J P Kastelein
Journal:  Int J Mol Sci       Date:  2022-08-20       Impact factor: 6.208

8.  Temporal changes in concentrations of lipids and apolipoprotein B among adults with diagnosed and undiagnosed diabetes, prediabetes, and normoglycemia: findings from the National Health and Nutrition Examination Survey 1988-1991 to 2005-2008.

Authors:  Earl S Ford; Chaoyang Li; Allan Sniderman
Journal:  Cardiovasc Diabetol       Date:  2013-01-30       Impact factor: 9.951

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.